Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Novartis’ Zykadia Sets New “Breakthrough” Speed Record For NME Review

This article was originally published in The Pink Sheet Daily

Executive Summary

FDA grants accelerated approval to ceritinib following a four-month review. The ALK inhibitor is indicated for non-small cell lung cancer patients who have progressed on or are intolerant of Pfizer’s Xalkori.

Advertisement

Related Content

Keeping Track: A Blizzard Of Submissions And A Small Flurry Of Approvals
Genentech’s Alecensa Joins The ALK Inhibitor Market
Accelerated Approval Conversion Could Mean ‘Breakthrough’ Loss
Cost-Benefit Of Early Access To NSCLC Drugs Evaluated In JAMA Study
CDER Builds Strong Foundation Of NMEs For 2014 As Approval Total Hits 20
CDER Builds Strong Foundation Of NMEs For 2014 As Approval Total Hits 19
Dose Finding At Breakthrough Speed: FDA Found A Role For Anecdotal Reports On Zykadia
FDA, Uninvited To Congress’ PCAST Hearing, Blogs Its Accomplishments
Novartis Counting On Depth Of Insight To Continue Success In Oncology
Pfizer's Crizotinib Eases Past FDA With Targeted Population

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS077152

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel